Targeting kidney inflammation as a new therapy for primary hyperoxaluria?
Adolescent
Adult
Animals
Calcium Oxalate
/ metabolism
Child
Child, Preschool
Disease Models, Animal
Humans
Hyperoxaluria, Primary
/ therapy
Infant
Inflammasomes
/ metabolism
Kidney
/ pathology
Kidney Failure, Chronic
/ complications
Kidney Transplantation
/ adverse effects
Macrophages
/ metabolism
Mice
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Nephritis
/ metabolism
Oxalates
/ metabolism
RNA Interference
Renal Dialysis
/ adverse effects
Renal Insufficiency
/ complications
Uric Acid
/ metabolism
Young Adult
NLRP3-inflammasome
calcium-oxalate
immune response
primary hyperoxaluria
renal failure
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
26
03
2018
pubmed:
1
9
2018
medline:
15
4
2020
entrez:
1
9
2018
Statut:
ppublish
Résumé
The primary hyperoxalurias (PHs) are inborn errors of glyoxylate metabolism characterized by endogenous oxalate overproduction in the liver, and thus elevated urinary oxalate excretion. The urinary calcium-oxalate (CaOx) supersaturation and the continuous renal accumulation of insoluble CaOx crystals yield a progressive decline in renal function that often ends with renal failure. In PH Type 1 (AGXT mutated), the most frequent and severe condition, patients typically progress to end-stage renal disease (ESRD); in PH Type 2 (GRHPR mutated), 20% of patients develop ESRD, while only one patient with PH Type 3 (HOGA1 mutated) has been reported with ESRD so far. Patients with ESRD undergo frequent maintenance (haemo)dialysis treatment, and finally must receive a combined liver-kidney transplantation as the only curative treatment option available in PH Type 1. In experimental models using oxalate-enriched chow, CaOx crystals were bound to renal tubular cells, promoting a pro-inflammatory environment that led to fibrogenesis in the renal parenchyma by activation of a NACHT, LRR and PYD domains-containing protein 3 (NALP3)-dependent inflammasome in renal dendritic cells and macrophages. Chronic fibrogenesis progressively impaired renal function. Targeting the inflammatory response has recently been suggested as a therapeutic strategy to treat not only oxalate-induced crystalline nephropathies, but also those characterized by accumulation of cystine and urate in other organs. Herein, we summarize the pathogenesis of PH, revising the current knowledge of the CaOx-mediated inflammatory response in animal models of endogenous oxalate overproduction. Furthermore, we highlight the possibility of modifying the NLRP3-dependent inflammasome as a new and complementary therapeutic strategy to treat this severe and devastating kidney disease.
Identifiants
pubmed: 30169827
pii: 5086497
doi: 10.1093/ndt/gfy239
doi:
Substances chimiques
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Oxalates
0
Calcium Oxalate
2612HC57YE
Uric Acid
268B43MJ25
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
908-914Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.